These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38537323)

  • 1. Strategies to promote implementation of core outcomes for medication adherence trials in rheumatology: A report from the OMERACT-Adherence Group.
    Kordkheili AM; Bekker C; Hoens AM; Voshaar M; Campbell W; Carmona L; de Wit M; March L; Nielsen SM; Shea BJ; Toupin-April K; Tugwell P; Tymms K; Kelly A;
    Semin Arthritis Rheum; 2024 Jun; 66():152411. PubMed ID: 38537323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.
    Kelly A; Tong A; Tymms K; March L; Craig JC; De Vera M; Evans V; Hassett G; Toupin-April K; van den Bemt B; Teixeira-Pinto A; Alten R; Bartlett SJ; Campbell W; Dawson T; Gill M; Hebing R; Meara A; Nieuwlaat R; Shaw Y; Singh JA; Suarez-Almazor M; Sumpton D; Wong P; Christensen R; Beaton D; de Wit M; Tugwell P;
    Trials; 2018 Mar; 19(1):204. PubMed ID: 29587864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group.
    Kelly A; Bartlett SJ; de Wit MP; Beaton DE; Dawson T; Evans V; Gill M; Hassett G; March L; Scholte-Voshaar M; Singh JA; Tong A; Tugwell P; Wong P; Tymms K
    J Rheumatol; 2019 Sep; 46(9):1202-1206. PubMed ID: 30647162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development.
    Humphrey-Murto S; Crew R; Shea B; Bartlett SJ; March L; Tugwell P; Maxwell LJ; Beaton D; Grosskleg S; de Wit M
    J Rheumatol; 2019 Aug; 46(8):1041-1046. PubMed ID: 30770512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.
    Boers M; Beaton DE; Shea BJ; Maxwell LJ; Bartlett SJ; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March L; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1021-1027. PubMed ID: 30770515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.
    Klokker L; Berthelsen DB; Woodworth T; Andersen KM; Furst DE; Devoe D; Williamson PR; Suarez-Almazor ME; Strand V; Leong AL; Goel N; Boers M; Brooks PM; March L; Sloan VS; Tugwell P; Simon LS; Christensen R
    J Rheumatol; 2019 Sep; 46(9):1173-1178. PubMed ID: 31043547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Preliminary Core Domain Set for Clinical Trials of Shoulder Disorders: A Report from the OMERACT 2016 Shoulder Core Outcome Set Special Interest Group.
    Buchbinder R; Page MJ; Huang H; Verhagen AP; Beaton D; Kopkow C; Lenza M; Jain NB; Richards B; Richards P; Voshaar M; van der Windt D; Gagnier JJ;
    J Rheumatol; 2017 Dec; 44(12):1880-1883. PubMed ID: 28089972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.
    Tieu J; Cheah JT; Black RJ; Christensen R; Ghosh N; Richards P; Robson J; Shea B; Simon LS; Singhi JA; Tugwell P; Boers M; Garibay MAA; Campochiaro C; Decary S; de Witt M; Fernandez AP; Keen HI; King L; Hinojosa-Azaola A; Hofstetter C; Gaydukova I; George MD; Gupta L; Lyne S; Makol A; Mukhtyar C; Oo WM; Petri M; Pisaniello HL; Sattui SE; Russell O; Teixeira V; Toupin-April K; Uhunmwangho C; Whitstock M; Yip K; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2021 Oct; 51(5):1139-1145. PubMed ID: 34253398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.
    Toupin-April K; Décary S; de Wit M; Meara A; Barton JL; Fraenkel L; Li LC; Brooks P; Shea B; Stacey D; Légaré F; Lydiatt A; Hofstetter C; Proulx L; Christensen R; Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Guillemin F; Beaton D; El-Miedany Y; Mittoo S; Westrich Robertson T; Bartlett SJ; Singh JA; Mannion M; Nasef SI; de Souza S; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Carrott D; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Umaefulam V; Monti S; Melburn C; Abaza N; Schultz K; Stones S; Kiwalkar S; Srinivasalu H; Constien D; King LK; Tugwell P
    Semin Arthritis Rheum; 2021 Jun; 51(3):593-600. PubMed ID: 33892937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.
    Toupin-April K; Barton JL; Fraenkel L; Meara A; Li LC; Brooks P; de Wit M; Stacey D; Légaré F; Shea B; Lyddiatt A; Hofstetter C; Christensen R; Scholte Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Karuranga S; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Beaton D; El-Miedany Y; Mittoo S; Bartlett SJ; Singh JA; Tugwell PS
    J Rheumatol; 2019 Oct; 46(10):1409-1414. PubMed ID: 30709963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.
    Andersen KM; Cheah JTL; March L; Bartlett SJ; Beaton D; Bingham CO; Brooks PM; Christensen R; Conaghan PG; D'Agostino MA; de Wit M; Dueck AC; Goodman SM; Grosskleg S; Hill CL; Howell M; Mackie SL; Richards B; Shea B; Singh JA; Strand V; Tugwell P; Wells GA; Simon LS
    J Rheumatol; 2019 Aug; 46(8):1053-1058. PubMed ID: 30647191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.
    Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks P; Day R; Strand V; Wells G
    J Rheumatol; 1999 Jan; 26(1):207-9. PubMed ID: 9918265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting.
    Toupin-April K; Barton J; Fraenkel L; Li LC; Brooks P; De Wit M; Stacey D; Légaré F; Meara A; Shea B; Lyddiatt A; Hofstetter C; Gossec L; Christensen R; Scholte-Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Pohl C; Jull JE; Sivarajah S; Campbell W; Alten R; Karuranga S; Morgan E; Kaufman J; Hill S; Maxwell LJ; Welch V; Beaton D; El-Miedany Y; Tugwell PS
    J Rheumatol; 2017 Oct; 44(10):1544-1550. PubMed ID: 28765239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings.
    Wohlfahrt A; Campos A; Iversen MD; Gagne JJ; Massarotti E; Solomon DH; Feldman CH
    PLoS One; 2018; 13(7):e0200886. PubMed ID: 30024938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.
    Mackie SL; Twohig H; Neill LM; Harrison E; Shea B; Black RJ; Kermani TA; Merkel PA; Mallen CD; Buttgereit F; Mukhtyar C; Simon LS; Hill CL;
    J Rheumatol; 2017 Oct; 44(10):1515-1521. PubMed ID: 28765246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing an Outcome Measures in Rheumatology (OMERACT) Core set of Outcome Measures for FOot and ankle disorders in RheumaTic and musculoskeletal diseases (COMFORT): core domain set study protocol.
    Chapman LS; Redmond AC; Flurey CA; Richards P; Smith TO; Arnold JB; Beaton D; Conaghan PG; Golightly YM; Hannan MT; Hofstetter C; Maxwell LJ; Menz HB; Shea B; Tugwell P; Helliwell P; Siddle HJ
    Trials; 2023 Jan; 24(1):65. PubMed ID: 36709309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
    J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.